Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 103Lung Neoplasms 49Ovarian Neoplasms 44Breast Neoplasms 31Small Cell Lung Carcinoma 25Neoplasms 20Fallopian Tube Neoplasms 16Triple Negative Breast Neoplasms 14Carcinoma, Ovarian Epithelial 14Neoplasm Metastasis 12Adenocarcinoma of Lung 11Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 7Lymphoma 7Head and Neck Neoplasms 7Carcinoma 7Urinary Bladder Neoplasms 6Esophageal Neoplasms 6Endometrial Neoplasms 6Brain Neoplasms 6Thoracic Neoplasms 5Prostatic Neoplasms 5Melanoma 5Lung Diseases 5Adenocarcinoma Of Esophagus 5Adenocarcinoma 5Respiratory Tract Neoplasms 4Recurrence 4

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Bladder Adenocarcinoma × Carboplatin × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡